Compass Therapeutics, Inc. (NASDAQ:CMPX), a biotechnology company focused on biological products, announced the election results for its board of directors following its Annual Meeting of Stockholders held on June 13, 2024. Stockholders voted to elect two Class I directors to serve until the 2027 Annual Meeting of Stockholders.
Ellen V. Chiniara, J.D., and Mary Ann Gray, Ph.D., were elected to the company's board with 76,766,213 and 100,051,792 votes for respectively, while 23,754,485 and 468,906 votes were withheld. There were also 17,705,143 broker non-votes for each nominee, indicating shares present at the meeting but not voted by brokers on behalf of shareholders.
Additionally, stockholders ratified the appointment of CohnReznick, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The decision was near-unanimous, with 118,180,952 votes for, 13,785 against, and 31,104 abstained, and no broker non-votes.
This information is based on a press release statement from Compass Therapeutics, Inc. The company, incorporated in Delaware with its principal executive offices in Boston, Massachusetts, is known for its development of biological products in the healthcare sector. The votes reflect the stockholders' confidence in the elected directors and their endorsement of the company's choice for its independent auditor for the upcoming fiscal year.
In other recent news, Compass Therapeutics has announced several significant developments. The biopharmaceutical company recently appointed Thomas Schuetz, M.D., Ph.D. as its new President and Chief Executive Officer. This leadership change comes as the company continues to advance its clinical programs and key clinical milestones.
In a separate development, Jefferies lowered the stock price target for Compass Therapeutics from $8.00 to $7.00, maintaining a Buy rating. This adjustment is due to a revised timeline for the company's pivotal bile duct cancer phase II/III data and an increase in the share count.
Compass Therapeutics also presented promising preclinical data at the American Association for Cancer Research Annual Meeting. The data suggests potential effectiveness of the company's proprietary antibodies, CTX-009 and CTX-471, against tumors resistant to current immune-oncology therapies. The company is advancing these product candidates through clinical development. These are recent developments in the company's operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.